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Background: There is a need for new antibiotics or combination of antibiotics that possess activity against increasingly resistant cystic ﬁbrosis (CF)
respiratory pathogens such as Pseudomonas aeruginosa and MRSA.
Methods: The antimicrobial activity of a novel 4:1 (w/w) fosfomycin:tobramycin (F:T) combination against CF respiratory pathogens under both
aerobic and anaerobic conditions was determined by MIC, time-kill and bioﬁlm studies, and compared with activity of fosfomycin and tobramycin,
individually.
Results: F:T and fosfomycin had excellent activity against P. aeruginosa and were more active than tobramycin against P. aeruginosa under an-
aerobic conditions with lower MIC50, MIC90 and geometric mean values. F:T (pb0.001) and fosfomycin (pb0.001) MICs for P. aeruginosa were
signiﬁcantly lower under anaerobic conditions with tobramycin MICs signiﬁcantly higher (pb0.001). F:T and fosfomycin also had high activity
against MRSA with both being more active than tobramycin. In time–kill studies, F:T was rapidly bactericidal against all 15 P. aeruginosa and 3/5
MRSA isolates tested. F:T also demonstrated bactericidal activity against P. aeruginosa grown in bioﬁlm under both aerobic and anaerobic
conditions.
Conclusions: F:T has promising in vitro antimicrobial activity against MRSA and P. aeruginosa with greater activity under anaerobic conditions
similar to those found in the CF lung.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Antibiotic therapy for CF patients is directed at preventing,
eradicating or controlling respiratory infection with oral, intra-
venous and inhaled antibiotics all extensively used. Current
standard of care guidelines recommend that inhaled antibiotics
should be used in all CF patients to delay or prevent chronic
Pseudomonas aeruginosa infection in patients when it is first
detected and for suppressive therapy in patients with chronic
P. aeruginosa infection [1]. Inhaled antibiotics such as tobra-
mycin [2] and aztreonam lysine [3] have been shown to im-
prove lung function and reduce exacerbation rate in patients
chronically infected with P. aeruginosa. Similarly, nebulized⁎ Corresponding author at: School of Pharmacy, Queen's University Belfast, 97 L
+44 28 90247794.
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doi:10.1016/j.jcf.2011.11.003vancomycin has been used as part of treatment protocols for
the eradication of meticillin resistant Staphylococcus aureus
(MRSA) in patients with CF [4].
Unfortunately, bacteria causing respiratory infection in CF
are becoming progressively more resistant to conventional anti-
biotics with increased resistance to aminoglycosides recently
highlighted as a particular concern [5]. As treatment options
are becoming increasingly limited, it is clear that there is a sig-
nificant unmet need for new antibiotics or combination of anti-
biotics that possess activity against increasingly resistant
respiratory pathogens such as P. aeruginosa and MRSA. Fur-
thermore, it is now widely accepted that sputum within the
lungs of CF patients contain anaerobic microenvironmentsisburn Road, Belfast, BT9 7BL, United Kingdom. Tel.: +44 28 90972087; fax:
by Elsevier B.V. All rights reserved.
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complex, S. aureus and anaerobes are growing in sputum under
these anaerobic conditions [6,7]. In addition, when chronic infec-
tion is established, pathogens such as P. aeruginosa grow within
biofilms in the CF lung and exhibit increased resistance to antibi-
otics [8–11]. Therefore, antibiotics with activity against bacteria
growing in biofilm under anaerobic conditions would be particu-
larly beneficial.
One such antibiotic currently in development is fosfomycin/
tobramycin for inhalation (FTI), an inhaled antibiotic with
broad-spectrum antibacterial activity for treatment of bacterial
respiratory infections. FTI consists of fosfomycin (F) and tobra-
mycin (T) in a 4:1 weight-to-weight ratio (w/w); this combina-
tion has been shown to be active, under aerobic conditions,
against a range of respiratory pathogens including P. aeruginosa
and S. aureus with no antagonism apparent [12]. The combina-
tion has also been shown to be active against P. aeruginosa grow-
ing in a biofilm under aerobic conditions [13]. Although, a
number of earlier studies have also reported a synergistic effect
of fosfomycin and other antibiotics [14,15], a recent review of
all the available literature concluded that additional studies with
more stringent definitions of synergy were required [16]. Signif-
icantly, the activity of fosfomycin against both gram-positive and
gram-negative bacteria has been shown to be greater under anaer-
obic conditions [15]. Given that bacteria causing CF pulmonary
infection persist within anaerobic niches in the lung, F:T may
be particularly effective for the treatment of polymicrobial CF
pulmonary infection under anaerobic conditions. Therefore, the
purpose of this study was to determine the in vitro activity of a
4:1 (w/w) F:T combination against CF respiratory pathogens,
growing planktonically and as biofilms, under both aerobic con-
ditions and also under anaerobic conditions which reflect in
vivo conditions in the CF lung and to compare this with activity
of fosfomycin and tobramycin, individually. We also investigat-
ed, using time–kill assays, whether the fosfomycin/tobramycin
combination was synergistic at this ratio under both conditions.
2. Materials and methods
2.1. Bacterial isolates
Twenty-five MRSA, 100 P. aeruginosa, 50 B. cepacia com-
plex and 25 anaerobic isolates were used for susceptibility test-
ing. The MRSA, P. aeruginosa and anaerobes (Veillonella,
n=12; Actinomyces, n=6; Prevotella, n=6; Propionibacterium,
n=1) tested were all clinical CF isolates. Of the 50 B. cepacia
complex isolates, 37 were clinical CF isolates and 13 were B.
cepacia complex panel strains. P. aeruginosa strain ATCC
27853, S. aureus strain ATCC 29213 and B. fragilis strain
ATCC 25285 served as quality control and reference strains.
2.2. Antibiotics and reagents
Fosfomycin disodium was purchased from Ecros (Barcelona,
Spain) and tobramycin sulphate was purchased from Chonqing
Imperial Biochem (Chongqing, China) with both antibiotics
USP grade. F:T consisted of a 4:1 (w/w) ratio of fosfomycinand tobramycin. Glucose-6-phosphate (G6P) and potassium
nitrate (KNO3) were both purchased from Sigma-Aldrich
(Gillingham, UK). Mueller Hinton agar (MHA, Oxoid Ltd,
Basingstoke, UK) and Mueller Hinton broth (MHB; Oxoid Ltd,
Basingstoke, UK) were supplemented with 1% (w/v) potassium
nitrate when testing P. aeruginosa to act as the terminal electron
receptor and allow for anaerobic respiration. G6P was added to
the media at a final concentration of 25 mg/L for all susceptibility
testing and time–kill assays.
2.3. MIC testing
Antibiotic stock solutions were prepared allowing for potency
and serially diluted 2-fold to give the following concentrations:
tobramycin, 0.125–512 mg/L; fosfomycin, 0.5–2048 mg/L
and F:T, 1.25–2560 mg/L. The initial inocula for MRSA,
P. aeruginosa and B. cepacia complex isolates were pre-
pared by incubating cultures overnight under both aerobic
and anaerobic conditions. The final inoculum for testing
was then prepared in MHB and the MICs determined by
the agar dilution method [17]. The MICs for anaerobic iso-
lates were also determined by the agar dilution method
[18]. F:T MIC values were expressed as the concentration
of both drugs (e.g. 20 mg/L=16 mg/L fosfomycin and
4 mg/L tobramycin). This data was used to calculate the con-
centration of the antibiotic combination and of each antibiot-
ic alone required to inhibit 50% (MIC50) and 90% (MIC90)
of the isolates and the percentage of isolates susceptible to
each antibiotic [17,18]. Antibiotic susceptibility was based
on parenteral breakpoints because resistant and susceptibility
breakpoints have not been established for inhaled antibiotics.
2.4. Time–kill studies
Time–kill experiments were performed according to CLSI
standards [19] to determine bactericidal activity of fosfomycin,
tobramycin and F:T (4:1 w/w ratio) and to assess synergy between
fosfomycin and tobramycin at this ratio. P. aeruginosa isolates
were grouped according to their aerobic F:T MIC: i. ≤10 mg/L;
ii. >10–≤20 mg/L and iii. >20 mg/L) with 5 isolates selected
from each group with MICs of 10, 20 and 40 mg/L, respectively.
Time–kill studies were performed for these 15 P. aeruginosa iso-
lates using F:T at a concentration of 2×aerobic MIC and both an-
tibiotics alone at the concentration used in the combination. In
addition, time–kill studies were performed for 5 MRSA isolates
with a range of MICs (2.5–20 mg/L) using F:T at a concentration
of 20 mg/L. A no drug control was run in each assay. Bacterial
cultures and antibiotics were incubated under both aerobic and an-
aerobic conditions at 37 °C and killing activity assessed at 0, 2, 4,
6 and 24 h. Antibiotic concentrations that reduced the original in-
oculum by ≥3 log10 cfu/mL were considered bactericidal. Syner-
gy was defined as a≥2 log10 decrease in total viable count at 24 h
by the combination compared with that by the most active single
agent and as a ≥2 log10 decrease in viable count compared with
the starting inoculum. Indifference was defined as a b1 log10
change in viable count at 24 h by the combination compared
with that by the most active single agent. Antagonism was defined
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compared with that by the most active drug alone [20].
2.5. Biofilm studies
Biofilm studies were performed in 96 well microtitre plates
(Nunc, NY, USA) using clinical P. aeruginosa and MRSA iso-
lates. Microtitre plates were pre-coated by overnight incubation
(4 °C) with 200 μL porcine stomach mucin (1 mg mL−1,
Sigma-Aldrich, St. Louis, USA) dissolved in sterile QSRS. Fol-
lowing incubation, mucin was decanted, the wells were washed
briefly with sterile QSRS and the plates were stored at 4 °C for
up to 3 weeks prior to use. Initial inocula were prepared as de-
scribed above and adjusted to provide a final inoculum density
of 1×107 cfu/mL with 200 μL added to each well and incubat-
ed overnight at 37 °C. Following biofilm formation, media was
removed and the wells were washed three times with 200 μL
sterile QSRS. Fresh broth (200 μL) containing antibiotic con-
centrations (Fof, 8–4096 mg/L; Tob, 2–1024 mg/L; F:T,
10–5120 mg/L) was then added and incubated at 37 °C for
24 h. Media was removed and the wells washed as described
above. To determine the number of viable bacteria in the bio-
film, sterile QSRS (200 μL) was added to each well and the
microtitre plates sonicated for 10 min at a frequency of
40 KHz using a Bransonic® 3510 Ultrasonic cleaner (Branson,
Danbury, USA). Suspensions in each well were then serially di-
luted 10-fold in QSRS and plated onto MHA for enumeration
after 24 h. Each test was performed in triplicate and the data
was used to calculate mean numbers of cells surviving at each
concentration together with standard deviation. Antibiotic con-
centrations that reduced biofilm total viable count by ≥3 log10
cfu/mL compared with the untreated control were considered
bactericidal.
2.6. Statistical analysis
MIC values for fosfomycin, tobramycin and F:T against P.
aeruginosa and MRSA were entered into the SPSS software
package. Statistical analysis was performed using the sign test
to compare values under aerobic and anaerobic conditions.
3. Results
3.1. MIC testing
Tobramycin was the most active inhibiting agent against P.
aeruginosa under aerobic conditions, having the lowest
MIC50, MIC90 and geometric mean values (Table 1). However,
both fosfomycin and F:T were more inhibitory than tobramycin
under anaerobic conditions having lower MIC50, MIC90 and
geometric mean values. Twenty-eight (28%) isolates were clas-
sified as susceptible to tobramycin under aerobic conditions
and this decreased to 6 (6%) under anaerobic conditions. In
contrast, 67 (67%) isolates were classified as susceptible to
fosfomycin under aerobic conditions and this increased to
94 (94%) under anaerobic conditions. These findings were
confirmed by analysis of the MIC distributions of P. aeruginosaisolates under both aerobic and anaerobic conditions (Fig. 1). Fos-
fomycin (pb0.001) and F:T (pb0.001) MICs for P. aeruginosa
were significantly lower under anaerobic conditions as indicated
by the clear shift toward lower MICs. In contrast, tobramycin
MICs for P. aeruginosawere significantly higher under anaerobic
conditions (pb0.001) as indicated by the clear shift toward higher
MICs.
Fosfomycin and F:T had high inhibiting activity against
MRSA isolates under both aerobic and anaerobic conditions
with both more active than tobramycin under both conditions
(Table 1). Sixteen of 25 (64%) isolates were classified as suscep-
tible to tobramycin under aerobic conditions and this decreased to
12 (48%) isolates under anaerobic conditions. In contrast, all 25
isolates were classified as susceptible to fosfomycin under both
aerobic and anaerobic conditions. Analysis of the MIC distribu-
tions of MRSA isolates under both aerobic and anaerobic condi-
tions confirmed these findings (Fig. 2). Fosfomycin MICs for
MRSA were significantly lower under anaerobic conditions
(pb0.001) as indicated by the clear shift toward lower MICs.
There was also a shift toward lower MICs for F:T when tested
under anaerobic conditions which approached statistical signifi-
cance (p=0.058). Similar to the findings for P. aeruginosa, tobra-
mycin MICs for MRSA were also significantly higher under
anaerobic conditions (pb0.001) as indicated by the clear shift
toward higher MICs.
F:T, fosfomycin and tobramycin had poor activity against
B. cepacia complex isolates under aerobic conditions with no
isolates susceptible to either tobramycin or fosfomycin
(Table 1). The susceptibility of B. cepacia complex isolates
was not tested under anaerobic conditions as growth was not
sufficient under these conditions. All three agents had moder-
ate inhibiting activity against the anaerobes tested (Table 1)
with F:T having the lowest MIC90 value (160 mg/L).
3.2. Bactericidal activity
The results of time–kill experiments are summarized in Table 2
with representative time–kill curves presented in Fig. 3. F:T
(2×aerobic F:T MIC) was rapidly bactericidal (2–4 h) under
both aerobic and anaerobic conditions against all 15 P. aeruginosa
isolates tested, with bactericidal killing maintained at 24 h
(Fig. 3a–d). For 6/15 isolates, killing was more rapid under anaer-
obic conditions, no difference was apparent for a further 8 isolates
with a single isolate killed more rapidly under aerobic conditions.
Tobramycin, at the concentration in the combination, was bacteri-
cidal against 13/15 and 12/15 P. aeruginosa isolates under aerobic
and anaerobic conditions, respectively. However, killing was
slower (2–24 h) than with F:T under both conditions (Fig. 3a
and b) and regrowth at 24 hwas apparent for one isolate under aer-
obic conditions and for 3 isolates under anaerobic conditions
(Fig. 3d). In contrast, fosfomycin, at the concentration in the com-
bination, was only bactericidal against 3 P. aeruginosa isolates
under anaerobic conditions and was not bactericidal against any
isolates under aerobic conditions. Similarly, fosfomycin was not
bactericidal against any MRSA isolates under aerobic conditions
and was bactericidal against only 2/5 MRSA isolates under
anaerobic conditions. F:T and tobramycin were both rapidly
Table 1
Antimicrobial susceptibility of clinical isolates grown under aerobic and anaerobic conditions.
Organism Antibiotic Aerobic Anaerobic Fold change
in geo mean
under anaerobic
conditions
Isolates with >4
fold MIC change
under anaerobic
conditions
MIC50/90
a MIC
range
Geo
mean b
Number (%)
susceptible c
MIC50/90 MIC range Geo
mean
Number (%)
susceptible
MRSA (n=25) TOB 1/>512 0.25–512 6.41 16 (64) 8/>512 2–512 27.86 12 (48) +4.35 12 (all increased)
FOF 4/8 b0.5–16 3.29 25 (100) d 1/2 b0.5–4 0.97 25 (100) −3.39 10 (all decreased)
F:T 2.5/20 1.25–20 4.12 N/A e 2.5/10 b0.625–10 3.30 N/A d −1.25 0
Pseudomonas
aeruginosa
(n=100)
TOB 16/32 1–128 11.79 28 (28) 64/128 2–256 36.50 6 (6) +3.10 11 (all increased)
FOF 64/256 2–2048 61.39 67 (67) d 32/64 0.5–1024 25.63 94 (94) −2.38 14 (all decreased)
F:T 40/160 2.5–160 47.90 N/A e 40/80 1.25–160 29.69 N/A d −1.61 4 (all decreased)
Burkholderia
cepacia
complex
(n=50)
TOB 256/512 64–>512 307.2 0 (0)
FOF >2048/>2048 1024–>2048 1998.0 0 (0) d
F:T 1280/>2560 640–>2560 1665.7 N/A e
Anaerobes (n=25) TOB 2/256 b0.125–>512 4.35 14 (56) f
FOF 4/>2048 b0.5–>2048 16.45 16 (64) f
F:T 5/160 b0.625–>2560 8.47 N/A d
a MIC results are reported as mg/L.
b Geo mean = geometric mean for population tested. Note where MIC values were lower than the lowest concentration tested the lowest concentration tested was
used to calculate Geo mean.
c MIC (mg/L) interpretive standards: tobramycin; sensitive≤4, intermediate 8, resistant≥16; fosfomycin; sensitive≤64, intermediate 128, resistant≥256.
d Only available CLSI breakpoints for fosfomycin are for Escherichia coli urinary tract isolates and these were used in the present study for P. aeruginosa and
MRSA.
e No breakpoints are available for F:T in CLSI guidelines.
f Percentage susceptible calculated using breakpoints for aerobic bacteria.
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F:Tmaintaining bactericidal killing at 24 h (Fig. 1e and f); howev-
er, these 3 isolates exposed to tobramycin under anaerobic condi-
tions experienced regrowth at 24 h (Fig. 1f).3.3. Antagonism
No antagonism was detected between fosfomycin and tobra-
mycin by the time–kill method for any of the 20 isolates tested
(MRSA, n=5; P. aeruginosa, n=15) under both aerobic and an-
aerobic conditions. The combination was categorized as synergis-
tic for 4 (20%) and indifferent for 16 (80%) isolates under aerobic
conditions. Under anaerobic conditions, the combination was
synergistic for 9 (45%) and indifferent for 11 (55%) isolates.3.4. Activity against biofilms
Activity against P. aeruginosa biofilms is shown in Fig. 4. F:T
was bactericidal at concentrations >20 mg/L under aerobic condi-
tions (Fig. 4e) with all concentrations tested bactericidal under an-
aerobic conditions (Fig. 4f). Fosfomycin was also bactericidal at
concentrations >32 mg/L under anaerobic conditions (Fig. 4b)
but did not demonstrate bactericidal activity under aerobic condi-
tions at any of the concentrations tested (Fig. 4a). Tobramycin was
not bactericidal against P. aeruginosa at any of the concentrations
tested under either condition (Fig. 4c and d). Similarly, F:T, fosfo-
mycin and tobramycin were not bactericidal againstMRSA in bio-
film under either aerobic or anaerobic conditions; however, under
anaerobic conditions, both F:T and fosfomycin demonstratedactivity against MRSA at higher concentrations with reduction
in viable counts of between 2 and 3 log10 apparent (data not
shown).
4. Discussion
FTI, a novel inhaled antibiotic combination consisting of
fosfomycin (F) and tobramycin (T) in a 4:1 weight-to-weight
ratio (w/w), is one of a number of antibiotics currently under
evaluation for aerosol administration in patients with CF and
other respiratory diseases characterized by chronic pulmonary
infection. This study investigated the in vitro activity of a 4:1
(w/w) F:T combination against CF respiratory pathogens and
compared this with the activity of both antibiotics individually.
As it is now widely accepted that sputum within the lungs of
CF patients contain anaerobic microenvironments [21] and
that hypoxic environments impact the activity of some classes
of antibiotics [22,23], we examined activity under aerobic con-
ditions and also under anaerobic conditions which are more rel-
evant to in vivo conditions in the CF lung.
OurMIC results show that F:T has promising inhibiting activity
against the frequently isolated CF pathogens, P. aeruginosa and
MRSA, and that the concentration of F:T required to inhibit
growth was lower under anaerobic conditions. Importantly, this
study is the first to show that an antibiotic under evaluation for
aerosol administration in CF patients has increased activity under
anaerobic conditions with F:TMICs for P. aeruginosa significant-
ly lower when tested under anaerobic conditions. Previously, King
et al. [22] reported that tobramycin, amikacin and aztreonam had
higher MICs for P. aeruginosa under anaerobic conditions and
Fig. 1. MIC distributions for clinical P. aeruginosa isolates (n=100) under aerobic and anaerobic conditions by antibiotic. (a) Tobramycin (TOB), (b) fosfomycin
(FOF) and (c) fosfomycin:tobramycin 4:1 (F:T).
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Similarly, Hill et al. [23] found that a range of antibiotics used in
the treatment of CF pulmonary infection including tobramycin,
amikacin, colistin and ciprofloxacin were less effective, both
alone and in combination, against P. aeruginosa under anaerobic
conditions. In agreement with the results of these studies, we
also found that tobramycin MICs for both P. aeruginosa and
MRSAwere significantly higher when tested under anaerobic con-
ditions with both F:T and fosfomycin more active than tobramycin
under anaerobic conditions. Fosfomycin when tested alone also
exhibited excellent inhibiting but not killing activity against both
P. aeruginosa and MRSA with activity greater under anaerobic
conditions. These results are consistent with previous studies that
have examined the activity of fosfomycin alone under these condi-
tions and found it has increased activity against gram-positive andgram-negative bacteria including P. aeruginosa and MRSA [15].
In agreement with the results of a number of previous studies
[12], F:T, fosfomycin and tobramycin all demonstrated poor activ-
ity againstB. cepacia complex isolates.We also assessed the activ-
ity of these agents against anaerobic bacteria cultured from CF
sputum as it is increasingly recognized that these bacteria may
have a role to play in the pathogenesis of CF lung infection
[6,7]. All three agents hadmoderate activity against obligate anaer-
obes with species dependent differences in susceptibility to F:T.
Further studies with larger numbers of clinical isolates from the
different genera detected in CF sputum are required to more fully
elucidate the antimicrobial effect of F:T against anaerobes.
Recent studies have noted a marked increase in the incidence
and prevalence of MRSA in CF patients with MRSA now colo-
nizing approximately 23% of patients with CF in the USA [24].
Fig. 2. MIC distributions for clinical MRSA isolates (n=25) under aerobic and anaerobic conditions by antibiotic. (a) tobramycin (TOB), (b) fosfomycin (FOF) and
(c) fosfomycin: tobramycin 4:1 (F:T).
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ated with a worse clinical outcome and a significantly higher rate
of death [25]. In the present study, F:T and fosfomycin were bothTable 2
Bactericidal activity of F:T, fosfomycin and tobramycin against clinical P. aerugino
Organism (no. of isolates) MIC (mg/L) F:T
Aerobic Anaerob
P. aeruginosa (n=5) 10 5/5 a 5/5
P. aeruginosa (n=5) 20 5/5 5/5
P. aeruginosa (n=5) 40 5/5 5/5
P. aeruginosa (n=15) c 10–40 15/15 15/15
MRSA (n=5) 2.5–20 4/5 3/5
a Data presented as number of isolates in each group in which antibiotic activity
b Number in brackets indicates number of isolates in group which had regrown a
c Data presented is a summary of data in lines 1–3.more inhibitory than tobramycin against MRSA, suggesting that
both may be good therapeutic agents for treatment of MRSA in
this patient population. However, although fosfomycin wassa and MRSA isolates under aerobic and anaerobic conditions.
Fosfomycin Tobramycin
ic Aerobic Anaerobic Aerobic Anaerobic
0/5 0/5 5/5 (1) b 5/5 (2)
0/5 1/5 5/5 5/5 (1)
0/5 1/5 3/5 2/5
0/15 2/15 13/15 (1) 12/15 (3)
0/5 2/5 3/5 3/5 (3)
was bactericidal (≥3 log10 cfu/mL reduction in original inoculum).
t 24 h.
Fig. 3. Representative time-kill curves for P. aeruginosa and MRSA isolates; (a) P. aeruginosa BA10 (MIC, 20 mg/L) aerobic, (b) P. aeruginosa BA10 (MIC,
20 mg/L) anaerobic, (c) P. aeruginosa CF49 (MIC, 10 mg/L) aerobic, (d) P. aeruginosa CF49 (MIC, 10 mg/L), (e) MRSA CFP8 (MIC, 2.5 mg/L) aerobic,
(f) MRSA CFP8 (MIC, 2.5 mg/L) anaerobic. Open circle, no drug; filled circle, FOF; open square, TOB; open triangle, F:T; broken line, bactericidal line.
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the development of resistance would preclude its use as a single
agent in routine practice. Several studies have shown that P. aer-
uginosa and S. aureus have a high mutation frequency to fosfo-
mycin resistance in vitro [12,26,27] with P. aeruginosa also
demonstrating a high mutation frequency when exposed to tobra-
mycin [12]. A recent study has also reported that there is no fit-
ness cost associated with the development of fosfomycin
resistance for P. aeruginosa leading the authors to conclude
that if fosfomycin were to be administered as a single agent the
development of resistance would be inevitable [27]. Furthermore,
the authors suggested that this would be of particular concern
in chronic respiratory infection caused by P. aeruginosa due to
the high prevalence of hypermutable strains [27]. However,
combining fosfomycin and tobramycin decreases P. aeruginosa
mutation frequency to levels that make the emergence of resis-
tance to both antibiotics improbable even in a hypermutablebackground [26,27]. Similar findings have also been reported
for S. aureus [12].
Time–kill studies demonstrated that F:T was rapidly bacteri-
cidal under both aerobic and anaerobic conditions with the
combination more active than either fosfomycin or tobramycin
individually. F:T maintained bactericidal killing at 24 h while
some isolates exposed to tobramycin experienced regrowth,
further highlighting the importance of using the combination
of both drugs to exert maximal effect under anaerobic condi-
tions. These results are consistent with previous findings that
the post-antibiotic effect of FTI was superior to that of fosfomy-
cin and tobramycin for P. aeruginosa and S. aureus, thereby
resulting in slower bacteria regrowth [12].
Examination of synergy by the time–kill method demon-
strated no interaction between fosfomycin and tobramycin for
the majority of isolates tested with no antagonism observed.
Our results are consistent with those reported between
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Fig. 4. Activity of tobramycin (TOB), fosfomycin (FOF) and fosfomycin:tobramycin 4:1 (F:T) against a CF P. aeruginosa isolate grown in biofilm; (a) FOF aerobic,
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170 G. McCaughey et al. / Journal of Cystic Fibrosis 11 (2012) 163–172fosfomycin and tobramycin [12] and between fosfomycin and
other aminoglycosides [28]. Furthermore, to the best of our
knowledge, the present study is the first to determine the interac-
tion between fosfomycin and tobramycin under anaerobic condi-
tions with the combination synergistic against more isolates
under anaerobic compared with aerobic conditions. It has been
previously shown that, under aerobic conditions, fosfomycin en-
hances the uptake of tobramycin resulting in increased inhibition
of protein synthesis and bacterial killing [29]. However, further
work is required to determine the mechanism which results inincreased activity of both fosfomycin and F:T under anaerobic
conditions and the mechanism of interaction between fosfomycin
and tobramycin under anaerobic conditions.
Given that P. aeruginosa pulmonary infection in CF patients
involves biofilm formation in an anaerobic environment [11],
we also determined the activity of F:T, fosfomycin and tobramy-
cin against clinical isolates grown in biofilm. Our results show
that F:T exhibits bactericidal activity against P. aeruginosa grow-
ing in biofilm under both aerobic and anaerobic conditions with
the combination being more effective than either agent alone.
171G. McCaughey et al. / Journal of Cystic Fibrosis 11 (2012) 163–172These results are in agreement with those of previous studies
which reported that the combination of an aminoglycoside and
fosfomycin was more effective than either agent alone against
P. aeruginosa biofilms grown under aerobic conditions [13,30].
Fosfomycin was also bactericidal against P. aeruginosa biofilms
under anaerobic conditions but only at much higher concentra-
tions than were effective in the combination. In contrast, tobra-
mycin was not bactericidal against P. aeruginosa at any of the
concentrations tested. Tobramycin activity is reduced under an-
aerobic conditions [22,31] and the lack of activity under aerobic
conditions may be explained by the presence of mucin in our bio-
film assay. Mucin, a major component of sputum that binds to
and reduces activity of tobramycin [22,32] was included in this
assay to more accurately reflect in vivo conditions within the
CF lung. Furthermore, our findings support those which have
previously shown that although bactericidal killing of bacteria
within the biofilm occurs, complete eradication is not achievable
[31,33]. This is consistent with the finding that chronic lung in-
fection with P. aeruginosa in CF is virtually impossible to eradi-
cate with antibiotic treatment [34].
In summary, this study has shown that F:T has excellent inhi-
biting and bactericidal activity against the frequently isolated CF
pathogens, P. aeruginosa and MRSA,. Furthermore, activity is
greater under anaerobic conditions, a particularly desirable proper-
ty, given that such conditions are present in the lungs of CF pa-
tients. In addition, F:T is bactericidal against P. aeruginosa
growing in biofilm in the presence of mucin under both aerobic
and anaerobic conditions. Therefore, F:T would be of particular
benefit in the treatment of P. aeruginosa infection in CF where
it is recognized that P. aeruginosa is growing as a biofilm under
microaerophilic or anaerobic conditions [11]. Given these poten-
tial advantages, F:T could be useful for the treatment of pulmonary
infections in patients with CF and other respiratory conditions
characterized by chronic pulmonary infection. Indeed, a phase 2
placebo controlled trial in patients with CF and P. aeruginosa
has recently reported that a 28 day course of FTI maintained
both the significant improvements in lung function and the reduc-
tions in P. aeruginosa sputum density achieved by a previously
administered 28 day course of inhaled aztreonam lysine [35,36].
As such, our results suggest that F:T has advantageous properties
that make it a potential new treatment option for the management
of chronic lung infection in the anaerobic environment present in
the lungs of CF patients.Conﬂict of interest statement
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